Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbCellera Biologics

Avidity Biosciences

Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener tools that can tease out such opportunities.

3 Highly Rated Biotech Stocks to Buy for 300% Gains

The consensus price target hints at an 186.4% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology to participate in upcoming March investor healthcare conferences.

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $0.76 per share a year ago.

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023. “Vir is poised to have a transformational year, with catalysts expected in the second and fourth quarters, which build off last year's clinical trial progress in our chronic hepatitis delta and B programs. We believe these data readouts, notably the SOLSTICE delta update in the second quarter, hold tr.

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Immuneering Corp

VistaGen Therapeutics

The global biotechnology market is a treasure trove of hidden-gem biotech stocks. Valued at $1.55 trillion in 2023, it is anticipated to grow at a CAGR of 13.96% from 2024 to 2030.

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024.

Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024

After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.

Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why

Arlo Technologies Inc

Catalyst Pharmaceuticals

Digi

Dynavax Technologies

Green Plains

Helix Energy Solutions Group

Ironwood Pharma

Ligand Pharmaceuticals

Livent Corp

ModivCare

Payoneer Global

Pacira Pharmaceuticals

Patterson-UTI Energy

Arcus Biosciences

SMART Global Hlds

Talos Energy Inc

Xencor

Xperi

The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized companies have also rallied, but not as much:

20 favorite small-cap stocks for 2024 among Wall Street analysts

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology makes strategic changes to focus capital allocation on programs with the highest potential for patient impact and value creation.

Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #JPM2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir Biotechnology Vi.

Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference

Agiliti Inc

AdaptHealth Corp

Digital Turbine

Clearfield

Cytek Biosciences

3D Systems

Enphase Energy

Harmony Biosciences Holdings

Lumen Technologies

Moderna

SunPower

According to a study published this summer in The Review of Financial Studies, these vulnerable stocks are the ones that are most difficult to borrow and then sell short.

Why these stocks could lose money even if the market gains

Arcos Dorados Hlds

AST SpaceMobile

BuildABear

Ginkgo Bioworks Holdings

Hudson Technologies

Redwood Trust

Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the potential giants of tomorrow, starting as small-caps and gradually ascending to large or even mega-cap status through consistent earnings expansion.

7 Small-Cap Stocks to Buy BEFORE the Year-End Rally

Avid Bioservices

NVIDIA

PulteGroup

Royal Caribbean Cruises

Tesla

Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, but also Royal Caribbean Cruises Ltd. NYSE: RCL and PulteGroup Inc. NYSE: PHM.

From laggards to leaders: Small caps on the rise

DISH Network

Enviri Corp

Organon & Co

REGENXBIO

Semtech

ViaSat

It's been all about the biggest of the big S&P 500 stocks all year. But now, investors are starting to look for big gains from small stocks.

It's Small Stocks' Time To Rally — Analysts Like These 11 Best

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HBV--Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD's The Liver Meeting® 2023.

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD's The Liver Meeting® 2023

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HBV--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include one late-breaking poster presentation and on.

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023

VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since. A new BARDA contract to develop a COVID antibody and another drug against a pathogen with pandemic potential has failed to lift the stock. Readouts from phase 2 work in Hepatitis B Virus and Hepatitis Delta patients are expected in Q4'23.

Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #Fast500--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. This is the first time in the 29-year history of the Deloitte Technology Fast 500 program that a company has topped the list for two consecutive years. The Company's revenue growth between.

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Phil Pang - Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Patrick Trucchio - H. C. Wainwright Nik Gasic - Leerink Partners Eva Privitera - TD Cowen Joseph Stringer - Needham & Company Operator Hello, and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call.

Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #TeamVir--Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results.

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #TeamVir--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company's research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will joi.

Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Mexico Fund

Schrodinger 

When investors think of Bill Gates stocks, they inevitably come up with Microsoft (NASDAQ: MSFT ), the software company he co-founded with Paul Allen in 1975 in Albuquerque. However, as Gates has spent less time around Microsoft's business, the billionaire has significantly diversified his investment portfolio.

3 Bill Gates Stocks to Buy for Billionaire-Like Returns

Arcellx

Apogee Therapeutics Inc

CRISPR Therapeutics

Immunome

Nuvalent

Prime Medicine Inc

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

7 Biotech Stocks to Get In Now Before Investors Catch On

News for Vir Biotechnology Stock (VIR)